BPM Presents Urine-Based Kidney Disease Risk Test at MEDICA 2026

By LabMedica International staff writers
Posted on 18 Nov 2026

Bio Preventive Medicine Corp. (BPM, Hsinchu County, Taiwan) showcases its DNlite urinary biomarker test at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. The company specializes in post-translationally modified protein biomarkers and in vitro diagnostics (IVD), focusing on identifying patients at risk of kidney disease progression before substantial deterioration in renal function occurs.

The featured DNlite (uPTM-FetA ELISA) test is designed to assess kidney function prognosis by measuring urinary post-translationally modified Fetuin-A (uPTM-FetA). The biomarker is associated with cellular stress involving kidney podocytes and tubular cells. The assay aims to distinguish patients at increased risk of rapid kidney function decline from those with more stable renal function.


Image: DNlite is designed to complement existing tests by providing additional prognostic information to support earlier risk assessment. (Photo courtesy of Bio Preventive Medicine Corp.)

Conventional kidney assessments rely on markers such as the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). However, these measurements may not fully capture early kidney injury or distinguish patients likely to experience rapid progression. DNlite is designed to complement existing tests by providing additional prognostic information to support earlier risk assessment.

The assay requires a routine random urine sample, avoiding the need for fasting blood collection or invasive procedures. Its ELISA format is intended for use in qualified clinical laboratories. DNlite provides prognostic information that can be considered alongside conventional clinical assessments, potentially supporting more individualized monitoring and treatment planning.

DNlite has obtained European Union In Vitro Diagnostic Regulation (IVDR) Class C certification for prognostic assessment in patients with type 2 diabetes and kidney transplant recipients. BPM reports commercial authorizations across more than 42 countries in Europe, the Middle East, Asia, and Latin America, supporting the test's availability in multiple international markets.

Clinical evidence supporting DNlite includes research involving participants from the CREDENCE trial. An analysis of 2,429 patients with type 2 diabetes and chronic kidney disease found that urinary uPTM-FetA independently predicted adverse renal outcomes beyond conventional markers, including UACR and eGFR. The findings suggest that the biomarker may provide additional information for identifying patients at increased risk of progression.

The company is also exploring the adaptation of its uPTM-FetA biomarker technology to automated clinical chemistry and chemiluminescence immunoassay platforms. These development initiatives aim to extend the test beyond its existing ELISA format and support integration into routine laboratory workflows through partnerships with diagnostic instrument manufacturers.

Additional collaboration opportunities include regional distribution, reference laboratory testing, pharmaceutical clinical trials, and integrated kidney care programs. BPM is investigating the potential use of its biomarkers to identify patients at increased risk of disease progression for clinical studies and support research into treatment monitoring and precision kidney care.

BPM exhibits at Booth C26-1 in Hall 3 within the Taiwan Flagship Pavilion. The company uses its participation at MEDICA 2026 to engage with diagnostic manufacturers, laboratory operators, healthcare providers, and research partners interested in urinary biomarker testing and kidney disease risk assessment technologies.


Latest Medica 2026 News